RxSight (RXST) Income from Non-Controlling Interests (2020 - 2024)
RxSight's (RXST) quarterly Income from Non-Controlling Interests came in at $155000.0 in Q4 2024, up 89.02% YoY from $82000.0 in Q1 2024, and up 3000.0% on a QoQ basis from $5000.0 in Q3 2024.
RxSight (RXST) Income from Non-Controlling Interests (2020 - 2024) Analysis & Trends
RxSight (RXST) has 5 years of Income from Non-Controlling Interests data on file, last reported at $155000.0 in Q4 2024.
- Quarterly Income from Non-Controlling Interests rose 89.02% year-over-year to $155000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $170000.0 (up 88.89% YoY) and the FY2025 annual result came in at $18000.0, down 89.47% from the prior year.
- Income from Non-Controlling Interests advanced to $155000.0 in Q4 2024, from $5000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $155000.0 in Q4 2024 to a low of -$87000.0 in Q4 2022.
- A 5-year average of $10473.7 and a median of $3000.0 in 2020 frame the typical range for Income from Non-Controlling Interests.
- The widest YoY moves for Income from Non-Controlling Interests: up 400.0% in 2022, down 8800.0% in 2022.
- Tracing RXST's Income from Non-Controlling Interests over 5 years: stood at $2000.0 in 2020, then slumped by 50.0% to $1000.0 in 2021, then slumped by 8800.0% to -$87000.0 in 2022, then jumped by 194.25% to $82000.0 in 2023, then soared by 89.02% to $155000.0 in 2024.
- The last three Income from Non-Controlling Interests figures came in at $155000.0 (Q4 2024), $5000.0 (Q3 2024), and $5000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn | - |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn | - |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn | 16.00 Mn |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn | -2.00 Mn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | -500,000.00 |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn | 13.00 Mn |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 2.32 Mn |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn | 900,000.00 |
| 10 | RxSight | 248.32 Mn | -155.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 155,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Mar 31, 2024 | 5,000.00 |
| Dec 31, 2023 | 82,000.00 |
| Sep 30, 2023 | 2,000.00 |
| Jun 30, 2023 | 2,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Dec 31, 2022 | -87,000.00 |
| Sep 30, 2022 | 5,000.00 |
| Jun 30, 2022 | 4,000.00 |
| Mar 31, 2022 | 3,000.00 |
| Dec 31, 2021 | 1,000.00 |
| Sep 30, 2021 | 1,000.00 |
| Jun 30, 2021 | 1,000.00 |
| Mar 31, 2021 | 2,000.00 |
| Dec 31, 2020 | 2,000.00 |
| Sep 30, 2020 | 3,000.00 |
| Jun 30, 2020 | 4,000.00 |